William Blair Issues Pessimistic Estimate for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued on Tuesday, February 18th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($1.46) per share for the quarter, down from their prior forecast of ($0.95). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share. William Blair also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($4.23) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $13.85 EPS.

AXSM has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a report on Wednesday. Leerink Partners upped their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, February 10th. HC Wainwright upped their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday. Royal Bank of Canada upped their target price on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Mizuho upped their target price on Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $157.64.

Axsome Therapeutics Stock Up 6.7 %

NASDAQ:AXSM opened at $137.75 on Friday. The stock has a market cap of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05. The stock has a 50-day moving average price of $101.29 and a two-hundred day moving average price of $94.84. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.37 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 22.40% of the company’s stock.

Institutional Trading of Axsome Therapeutics

A number of large investors have recently bought and sold shares of the business. Pitcairn Co. grew its stake in shares of Axsome Therapeutics by 3.4% in the 4th quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock valued at $386,000 after buying an additional 148 shares during the period. Meridian Wealth Management LLC boosted its stake in Axsome Therapeutics by 0.7% during the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock valued at $1,791,000 after purchasing an additional 150 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in Axsome Therapeutics by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company’s stock valued at $326,000 after purchasing an additional 162 shares during the last quarter. Arizona State Retirement System boosted its stake in Axsome Therapeutics by 1.8% during the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock valued at $766,000 after purchasing an additional 164 shares during the last quarter. Finally, Intrust Bank NA boosted its stake in Axsome Therapeutics by 6.9% during the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock valued at $239,000 after purchasing an additional 183 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.